drugset / Trial / NCT05801237
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor.
Timeline
- Start
- 2023-09-21
- Primary completion
- 2026-09
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PE0105 | Monoclonal antibody | — | — |
| Subject | PE0116 | Monoclonal antibody | — | — |
Indications
No indication recorded.